Autopsy report · NCT04261777

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

“The study was closed prematurely in order to finalise it under EU directive 2001/20/EC, without transitioning to EU-CTR, and avoiding unnecessary delay of the marketing authorisation application.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 4 years 8 months before it stopped.
• 172 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Saving Patients' Lives Medical B.V.

Sponsor type

Industry

Conditions

Prostate Cancer; Metastasis; Prostatectomy

Interventions

Ferrotran® (Ferumoxtran-10)

Participants

172

Sites

15

Countries

Belgium, Germany, Netherlands, Switzerland

Trials that died the same way

• A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
  “The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.” (60% match in meaning)
• Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
  “The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA)” (60% match in meaning)
• Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  “The study was closed due to the end of funding.” (58% match in meaning)
• Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
  “The study closed prior to enrolling any participants.” (58% match in meaning)
• Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
  “This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.